Європейський Союз - англійська - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - multiple sclerosis - selective immunosuppressants - lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features.

Європейський Союз - англійська - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.

Європейський Союз - англійська - EMA (European Medicines Agency)

roche registration gmbh  - pertuzumab - breast neoplasms - antineoplastic agents, monoclonal antibodies - metastatic breast cancer:perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.neoadjuvant treatment of breast cancer:perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

Канада - англійська - Health Canada

bristol-myers squibb canada - elotuzumab - powder for solution - 440mg - elotuzumab 440mg - antineoplastic agents

Канада - англійська - Health Canada

bristol-myers squibb canada - elotuzumab - powder for solution - 340mg - elotuzumab 340mg - antineoplastic agents

Канада - англійська - Health Canada

pfizer canada ulc - inotuzumab ozogamicin - powder for solution - 0.9mg - inotuzumab ozogamicin 0.9mg - antineoplastic agents

Канада - англійська - Health Canada

pfizer canada ulc - gemtuzumab ozogamicin - powder for solution - 4.5mg - gemtuzumab ozogamicin 4.5mg - antineoplastic agents

Канада - англійська - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - alemtuzumab - solution - 12mg - alemtuzumab 12mg - antineoplastic agents

США - англійська - NLM (National Library of Medicine)

genentech, inc. - pertuzumab (unii: k16aiq8ctm) (pertuzumab - unii:k16aiq8ctm), trastuzumab (unii: p188anx8ck) (trastuzumab - unii:p188anx8ck), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - phesgo is indicated for use in combination with chemotherapy for - the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see dosage and administration (2.2) and clinical studies (14.2)] . - the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence [see dosage and administration (2.2) and clinical studies (14.2)] . select patients for therapy based on an fda-approved companion diagnostic test [see dosage and administration (2.1)]. phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration (2.2) and clinical studies (14.1)] . select patients for therapy based on an fda-approved compa

Канада - англійська - Health Canada

hoffmann-la roche limited - pertuzumab - solution - 420mg - pertuzumab 420mg - antineoplastic agents